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Summary The pattern of acquired mutations in the p53 tumour-suppressor gene is potentially useful for
determining factors contributing to carcinogenesis in diverse populations differing in incidence and/or mortality
from the disease. We previously reported differences in mutational patterns of the p53 gene in primary breast
cancers from Midwest US Caucasian, African-American and Austrian women. Herein, we report 16
mutations in 27 primary breast cancers from Japanese women from Hirosaki, a population with a low
incidence of breast cancer. The frequency of 59.3% of p53 mutations is the highest reported in breast cancers
from a particular ethnic group thus far. A relatively high number of mutations (7/16) were heterozygous in at
least some tumour cell clusters. Intergroup comparisons of the mutational pattern between this population and
several other US, European and Japanese populations do not show any statistically significant differences.
There were recurrent mutations at two sites, codon 273 (R-.H; three mutations), a common hotspot of
mutations in breast and other cancers, and codon 183 (S-Stop; two mutations), a very rare location for p53
mutations. These mutations were shown to be independent and presumably not in the germ line. The highest
frequency ofp53 mutations raises the possibility that p53 mutagenesis is a predominant factor for breast cancer
development in this low-risk Japanese group, whereas in other cohorts different mechanisms are likely to
account for the higher proportion of breast cancer. Further studies are needed to confirm the present
observations.
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The pattern of acquired mutations in the same region of a
particular gene in a particular type of cancer offers the
possibility of detecting differences in mutagenic processes
contributing to carcinogenesis in diverse populations differing
in incidence and/or morbidity from the disease (Shields and
Harris, 1991; Jones et al., 1991). The mutational pattern of
the p53 gene is a useful epidemiological tool as a 'mutagen
test' (Sommer, 1990) because this gene is altered frequently in
nearly all types of human cancer (reviewed in Harris and
Hollstein, 1993). In human breast cancers, the frequency of
p53 gene mutations ranges from 20% to 40% in various US
American, European and Japanese populations (Coles et al.,
1992; Mazars et al., 1992; Sommer et al., 1992; Tsuda et al.,
1993; Andersen et al., 1993; Thorlacius et al., 1993; Blaszyk
et al., 1994; Hartmann et al., 1995a,b).
We are investigating the pattern of p53 gene mutation in
sporadic breast cancer in racially and geographically diverse
populations with different risks for this disease. We assume
that the patterns of mutation in high-risk populations reflect
the superimposition of a pattern caused by a unique or
enhanced exposure to a particular environmental toxin(s)
upon an intrinsic (endogenous) pattern of mutation
characteristic of low-risk groups. We have shown that the
pattern of p53 gene mutations in primary breast cancers in a
white, largely rural Midwestern US population (Sommer et
al., 1992; Saitoh et al., 1994) and in a population from Graz,
Austria (Hartmann et al., 1995a), differs significantly from
the pattern present in African-American women from
Detroit (Blaszyk et al., 1994) and from the patterns in
Scottish (Coles et al., 1992) and French (Mazars et al., 1992)
women. The major differences among these populations are:
a predominance of transversions, particularly G:C-+T:A
transversions in the Scottish population; a high frequency
of microdeletions in the rural white US population; a high
frequency of A:T-+T:A transversions in the Austrian
population; and a high frequency of transitions, particularly
A:T-+G:C transitions, in the African-American population.
The implication is that different endogenous and/or
exogenous factors contribute to breast carcinogenesis to
different extents in these populations.
Japanese women have a very low breast cancer risk with
age-adjusted incidence and mortality rates per 100 000 per
year (30-74 years of age) of 54.4 and 12.6 respectively
(Coleman et al., 1993). For US American and Scottish
women these numbers are 3-4 times higher (USA, 183.2 and
46.1; and Scotland, 132.1 and 57.5; Coleman et al., 1993;
Boring et al., 1993). To investigate the frequency and pattern
of p53 mutations in a population with a low-risk of the
disease and to compare the results with the mutational
patterns of the high-risk groups studied, 27 unselected
primary breast cancers from Japanese women living in
Hirosaki, Japan, were analysed. Sixteen mutations (59.3%)
were found. This is the highest frequency of mutation in the
p53 gene in breast cancers reported to date.
Materials and methods
Human tissue samples
Twenty-seven primary breast cancers collected consecutively
from the Department of Surgery in Hirosaki, Japan, were
analysed. Samples were snap frozen in liquid nitrogen,
shipped to Rochester, MN, USA, on dry ice, and stored at
-70°C until the time of analysis. Touch preparations from
the partially thawing cut surface of frozen tissue were made
as described previously (Kovach et al., 1991). Small clusters
of pure tumour cells adherent to the slide were stained by
brief dipping in a methylene blue-toluidine blue solution.
After rinsing in tap water, clusters of 30-100 malignant cells
were lifted from the slide on the tip (0.1 mm in diameter) of a
hand-held glass pipette. The clusters were placed in 5 MI of
0.5% dextrose in water in a 0.6 ml sterile microfuge tube and
processed for amplification or stored frozen at -70°C.
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Cells from frozen samples were lysed by the addition of
proteinase K in a solution of sodium dodecyl sulphate (SDS).
The p53 gene was amplified in three segments by nested
amplification as described previously (Sommer et al., 1992;
Saitoh et al., 1994). Thirty-five cycles of polymerase chain
reaction (PCR) were performed with each of two sets of
primers. One microlitre of the total volume of the first
amplification mixture was used as a template for the second
round of amplification.
Dideoxy fingerprinting
Sommer et al. developed an efficient technique for detecting
mutations called dideoxy fingerprinting (ddF) (Sarkar et al.,
1992). ddF combines dideoxy sequencing and single-stranded
conformation polymorphism (SSCP) gel analysis for the
detection of single base and other sequence changes in PCR
amplified segments. In brief, a Sanger sequencing reaction is
performed with only one of the four dideoxynucleotides. The
sample is then electrophoresed on a non-denaturing gel. The
presence of a mutation is detected by an abnormal migration
pattern in any of the dideoxy-terminated segments containing
the mutation and/or by an alteration of the numbers of
segments due to a loss or a gain of the deoxynucleotide
corresponding to the dideoxynucleotide used in the reaction.
ddF detected 84 of 84 different types of point mutations in
the factor IX gene (Sarkar et al., 1992). In addition, ddF
detected all 25 mutations among 73 breast cancers of our
white Midwestern population found by direct genomic
sequencing of the p53 gene (Blaszyk et al., 1995).
Sequencing
All regions of abnormality detected by ddF were sequenced
in both directions using genomic amplification with transcript
sequencing (GAWTS; Stoflet et al., 1988; Sommer and
Vielhaber, 1994) and sequencing primers as previously
described (Sommer et al., 1992; Saitoh et al., 1994). All
mutations were confirmed by amplification and direct
sequencing of at least one separate cluster of tumour cells
from a touch preparation.
Genotype and haplotype analysis
To investigate the possibility that the mutations at amino
acid 273 (113T, 114T and 115T) and amino acid 183 (lIOT
and 202T) are due to errors during tissue sampling or other
artefacts, several highly polymorphic di- and trinucleotide
repeats in various regions of the genome and several
polymorphisms within the p53 gene were investigated in
these five tumours. Six short tandem repeats (D2S147,
D2S197, D2S123-Weissenbach et al., 1992; CTGB37-Li et
al., 1993; AR-La Spada et al., 1992; DM-Brook et al.,
1992) were amplified by PCR using Pfu polymerase and a
protocol developed for amplification of regions with a high
G/C content (Dutton et al., 1993). PCR reactions were
performed in 50 il reactions containing the DNA from one
tumour cell cluster (approximately 5-10 ng), 1 giM of each
primer, 200 ,UM each of dATP, dTTP and dGTP, 20 ,UM
dCTP, 0.5 mCi[x_-32P]dCTP, 1.25 U Pfu DNA polymerase
(Stratagene), and 5 MI 10 x reaction buffer [200 mM Tris-HCI
pH 8.2, 100 mm potassium chloride, 60 mM ammonium
sulphate, 20 mM magnesium sulphate, 1% Triton X-100, 100
ng ul-' nuclease-free bovine serum albumin (BSA) over 35
cycles consisting of 1 min at 98°C, 2 min at 62°C and 4 min
at 70°C for D2S123 and (AR) and of 1 min at 98°C and 5
min at 70°C for all other repeats with a final extension of 10
min at 70°C. The PCR primer sequences are available upon
request. The PCR products were electrophoresed through 6%
polyacrylamide gels containing 7.7 M urea for 3 h. After
electrophoresis the gels were dried and exposed to X-ray film.
Eleven tumours were screened for every repeat (the five
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tumours with mutations at amino acids 273 and 183 and six
control tumours with different mutations) (Figure 1).
The following polymorphisms within the p53 gene were
screened either by PCR (CA-repeat) or by direct sequencing
as described above: a dinucleotide repeat polymorphism
(Jones and Nakamura, 1992), a C/G polymorphism in intron
2 37 bp 3' from exon 2 (Pignon et al., 1994), a 16 bp insertion
polymorphism in intron 3 15-23 bp 3' of exon 3 (Lazar et
al., 1993), a C/G (Pro/Arg) polymorphism at codon 72 in
exon 4 (Matlashewski et al., 1987) and an A/G polymorph-
ism in intron 6 61 bp 3' of exon 6 (Chumakov and Jenkins,
1991).
a
1 2 3 4 5 6 7 8 9 10 11 12
b
1 2 3 4 5 6 7 8 9 10 11 12
c
1 2 3 4 5 6 7 8 9 10 11 12
Figure 1 Examples of autoradiographs of the genotypic
fingerprinting with highly polymorphic di- and trinucleotide.
repeats of the tumours with exactly the same mutation. (a)
CTG B37, (b) DM, (c) D2S123. Lanes 1 -3, tumours with
mutation at amino acids 273 (1 13T, 114T, 1 15T); lanes 4-6,
tumours with mutation at amino acids 183 (1lOT, 1OT second
sample, 202T); lanes 7-12, control tumours (193T, 194T, 195T,
197T, 199T, 200T).p53 mutations in breast cancer in Japanese women
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Immunohistochemical detection ofp53 antigen overexpression
Clusters of tumour cells in touch preparations were stained
for expression of p53 as described previously (Kovach et al.,
1991; Sommer et al., 1992). Briefly, the touch preparations
were incubated with each of three p53-specific monoclonal
antibodies (PAb 1801, 0.5 ,g ml-', Cambridge Research
Biochemicals; PAb 240 1 ,ug ml-', Santa Cruz Biochemicals;
and PAb 421, 1 ,ig ml- ', Oncogene Sciences). Bound
antibody was detected with an avidin-biotin complex Elite
kit (Vector) as directed by the manufacturer. Normal mouse
IgG reagent was used as a negative control; tumour samples
with p53 missense mutations, which show strong nuclear
staining with all three antibodies, were used as positive
controls. Tumours with 5% or more cells expressing p53 to
any of the antibodies were considered immunohistochemi-
cally positive. Each experiment was repeated at least once to
verify the results.
Statistical analysis
The patterns of mutation in breast cancer for the different
populations were compared by the Fisher exact test using the
Stat X Act software package (Cytel).
Results
Frequency and allelic status ofp53 gene mutations
Sixteen mutations were detected among 27 breast cancers
(59.3%) upon analysis of exons 4-10 and the adjacent
intronic sequences of the p53 gene (Table I). There were eight
missense mutations, two nonsense mutations, four frameshift
microdeletions/microinsertions and two mutations that alter a
consensus splice sequence (one single base change and one
inframe microdeletion/insertion). In contrast to findings in
the US Caucasian, US African-American and Austrian
populations previously studied (Saitoh et al., 1994; Blaszyk et
al., 1994; Hartmann et al., 1995a), in which wild-type
sequence was absent from virtually all mutated tumours, 5
of 16 mutations were heterozygous in all cell clusters
examined. Two other tumours showed a heterozygous
pattern in at least one of the investigated tumour cell clusters.
Clustering ofp53 mutations
Recurrent mutations were found at two sites. A transition at
the dinucleotide CpG produced an arginine to histidine
substitution at codon 273 in three tumours (1 13T, 114T and
11 5T) and a C:G-+G:C transversion produced a nonsense
mutation at codon 183 in two tumours (1 lOT and 202T,
Table I). To exclude the possibility of sample duplication or
other artefact, six highly polymorphic di- and trinucleotide
repeats in various regions of the genome were investigated in
these five tumours by PCR. The three tumours with a
mutation at amino acid 273 (113T, 114T and 115T) differed
in at least three of the six polymorphic alleles, demonstrating
that the mutations are independent. Investigation of the two
tumours with the same mutation at amino acid 183 showed
different alleles in three of six repeats (Figure 1). Thus, five
independent mutations occurred at two mutational hotspots,
making up 31% of 16 mutations found. Whereas, a mutation
at amino acid 273 is a common change in breast and other
types of cancer, only one mutation at amino acid 183 among
1965 p53 mutations has been reported among various cancers
(De Vries et al., 1996). There was no constitutional DNA
available, so the possibility of germline mutations cannot be
formally excluded. However, to exclude the possibility that
the individuals with these mutations in our study had
common ancestors, several polymorphisms were investigated
within the p53 gene (see Materials and methods and Table
III). Two polymorphisms were informative. A highly
polymorphic dinucleotide repeat within p53 gene and a
common polymorphism at amino acid 72 indicated that all
five tumours with independent mutations were associated
with different haplotypes. Furthermore, there was no family
history of cancer in these patients.
Pattern of mutation
There were 16 independent mutations among 27 tumours.
Because most studies of p53 gene mutations are limited to
exons 5-9, for comparisons of patterns of mutations among
different populations, we analysed the 15 mutations within
this region of the gene. Mutations were classified into eight
groups: deletions/insertions, G:C-+A:T transitions at the
dinucleotide CpG, G:C-+A:T transitions not at CpG,
Table I Mutations in exons 2 11 in the p53 gene in primary breast cancers from Hirosaki, Japan
Immunohistochemistry: nuclear
Tumour Exonl Nucleotide Structural change reactivity with antibodyc Mutation Allelic
no. Age Stage" intron changeb codonlamino acid PAbJ8O1 PAb240 PAb421 type statusd
194T 61 IIIA E6 TGG(C-*T)CCC 189 A-+V + Missense Heterozygous
204T NA NA E6 AGT(G-*A)TGG 216 V--M + + + Missense Heterozygous
199T 57 IIIA E6 CCT(A-*G)TGA 220 Y-+C + + + Missense Hemi/
Heterozygousf
70T 47 I E7 GTA(A-+C)CAG 239 N-*T + + + Missense Hemizygous
113T 46 IIA E8 TGC(G-oA)TGT 273 R-*H + Missense Hemizygous
114T 81 IIIA E8 TGC(G-*A)TGT 273 R--H + + + Missense Hemizygous
li5T 41 IIB E8 TGC(G-A)TGT 273 R--H - Missense Hemizygous
69T 67 IIIA E8 ACA(G-A)AGG 285 E-+K + + - Missense Hemizygous
453Te NA NA E4 ACT (TGCACGg-+a)tca 124-125 7 bp deletion - + - Deletion (IF) Hemizygous
1 bp insertion splice site
193T 60 IIB E5 TCA(--CA)ACA 131 2 bp insertion - + - Insertion (FS) Heterozygous
lIOT 83 IIA E5 GCT(C-,G)AGA 183 S-*stop - + - Nonsense Hemizygous
202T NA NA E5 GCT(C-G)AGA 183 S-*stop - + - Nonsense Hemizygous
195T 40 IIA E7 ACT(-T)ACA 236 1 bp insertion - + - Insertion (FS) Hemizygous
197T 63 IIIB E7 TGT(GTA-+TT) ACA 238 3 bp deletion - + - Deletion/ Heterozygous
2 bp insertion 236 insertion (FS)
7lTe 66 IIB E9 ACC(AGCTC)CTC 313 -14 5 bp deletion + + - Deletion (FS) Hemi/
heterozygousf
200Te 62 IIA 19 CAG(g-*t)tac First 5' base of intron 9 + + - Splice site Heterozygous
aAmerican Joint Committee on Cancer (3rd edn). bSmall characters are intronic sequence. cTumours with 5% or more cells expressing p53 to any
ofthe three antibodies were considered immunohistochemically positive. dThe hemi- or heterozygous status ofa tumour cell cluster wasjudged on
the basis ofthe presence or absence ofwild-type sequence at the site ofthe mutation. eTumour cell clusters were either hemizygous or heterozygous
for the p53 mutation. fPreviously reported in Hartmann et al. (1995b). IF, inframe; FS, frameshift.p53 mutations in breast cancer in Japanese women
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The pattern of mutation in the Hirosaki population was
compared with our Midwestern white population (Sommer et
al., 1992; Saitoh et al., 1994), a US African-American
population from Detroit (Blaszyk et al., 1994), to pooled data
from several western European populations (Coles et al.,
1992; Mazars et al., 1992; Andersen et al., 1993; Thorlacius et
al., 1993) and to two populations from Tokyo and
Tokushima (Tsuda et al., 1993; Sasa et al., 1993). Pairwise
comparisons among populations did not show statistically
significant differences in patterns of p53 mutations between
the Hirosaki sample and others (Table II).
Immunohistochemistry
Touch preparations were stained with three monoclonal p53
antibodies, PAb 1801, PAb 240 and PAb 421 (Table I).
Among eight tumours with a missense mutation present, six
were positive for p53 expression as assessed by nuclear
staining with PAb 1801. Five of these also stained with PAb
240 and four with PAb 421. Only one of the three tumours
with a missense mutation at codon 273 (114T) stained with
all three antibodies; one tumour stained with PAb 1801 only
(113T) and tumour 15T did not stain with any of the three
antibodies. Eight tumours contained a null mutation
(nonsense, frameshift or splice site mutations). Six of these
did not react with PAbl801 and PAb 421 as expected for
tumours with null mutations. The other two, 71T and 200T,
which contained a frameshift deletion towards the C-terminal
end of the gene and a splice site mutation in intron 9
respectively, reacted with PAb 1801 but not PAb 421,
suggesting overexpression of a portion of the p53 protein.
Discussion
Frequency ofp53 mutation
Although the number of tumours investigated in this study is
low, the high frequency of mutations in the p53 gene (55.5%
in exons 5-9) is striking when compared with the frequencies
of p53 mutations in the same exons in breast cancers in
various European populations (pooled data; 21.6%;
P=0.0002), in a US Midwestern white population (29.9%;
P= 0.02), in a US African-American population from
Detroit (34%; P=0.08) and in Japanese women from Tokyo
(24.6%; P=0.002) and from Tokushima (24.6%; P=0.007)
(references in Table II). Although an unknown bias in sample
collection among the various populations cannot be ruled
out, this is unlikely. No statistically significant differences in
various tumour parameters, including tumour size, sage,
lymph node involvement and histological type were observed
between the Hirosaki and the US patients, and the same
techniques were used to detect and confirm mutations.
Oncoproteins from several DNA tumour viruses, such as
the SV40 large T antigen, the adenovirus E1B and
papillomavirus E6 protein are known to functionally
inactivate wild-type p53 protein by binding to or by
degrading the protein. The cellular oncogene MDM2, which
is frequently amplified in sarcomas, is believed to decrease
p53 function by binding to wild-type p53 (Momand et al.,
1992; Oliner et al., 1993). If p53 mutagenesis is but one of
several mechanisms responsible for breast carcinogenesis, the
high frequency of p53 mutations in a low-risk group such as
women from Hirosaki raises the possibility that in this group
p53 mutagenesis is a predominate factor in breast cancer
development whereas in other cohorts different mechanisms
are likely to account for the higher proportion of breast
cancer.
We are studying additional patients to confirm the
difference in frequencies of p53 gene mutations between
southern and northern Japanese populations and to
determine if the mutations at codons 183 and 273 are
favoured targets in the northern group.
Allelic status of the mutations
Another intriguing characteristic of p53 mutations in breast
cancers of Japanese women from Hirosaki revealed by our
Table II Mutations in exons 5 -9 of the p53 gene in breast cancers from Japanese, US and European patients
Transitions Transversions
No. of mutations G:C-*A:T G:C-.A:T A:T-*G:C
Origin ofpatients (% of tumours) Deletion/insertion CpG non-CpG G:C-+C:G G:C-*T:A A:T-*C:G A:T-+T:A
Japan, Hirosaki 15 (55.6) 4 3 3 1 2 1 1 0
Midwest US 29 (29.9) 11 6 6 1 2 0 1 2
Rural Whitea
US African 16 (34.0) 1 5 2 5 1 1 1 0
Americanb
Europeansc 109 (21.6) 14 26 19 9 7 19 11 4
Japan, Tokyod 29 (24.6) 6 5 6 7 0 1 2 2
Japan, Tokushimae 16 (24.6) 1 5 2 2 1 1 1 3
aSommer et al. (1992); Saitoh et al. (1994)."Blaszyk et al. (1994). cPooled data from Scotland: Coles et al. (1992); France: Mazars et al. (1992);
Norway: exons 5-8, Andersen et al. (1993); Iceland: exons 5,7,8, Thorlacius et al. (1993). All pairwise comparisons ofthe pattern in these cohorts
were not statistically significant. dTsuda et al. (1993). eSasa et al. (1993) (exons 5-8).
Table III Comparison of the samples with the mutations at amino acids 183 and 273
Structural
change p53 gene
codon/ Datafrom Hirosaki Date of Immunohistochemistry polymorphism
Tumour amino acid clinical Received surgery Age PAbJ801 PAb240 PAb241 at amino acid 72
113 273 R-.H Solid tubular T2NOMO (II) E, P-.not done 9/6/91 8/10/88 46 + + Pro
114 273 R--H Solid tubular TINOMO (I) E-, P1 9/6/91 4/16/91 81 + + + Arg
115 273 R--H Scirrhous (T3N2MO (III) E+, P+ 9/6/91 5/31/91 41 - Pro/Arg
202 183 S-*stop Solid tubular T2NlMO E, P-. not done 2/17/92 NA NA - + Arg
110 183 S-.stop Solid tubular T2NOMO (II) E+, P+ 9/6/91 7/3/91 83 - - Arg
Highly polymorphic repeats: 113T, 114T, lI5T are different from'each other in three repeats: 202T is different in three repeats from 1lOT.
Polymorphisms within the p53 gene: insertion polymorphism in intron 3 and the polymorphisms in intron 2 and intron 6 are not informative;
polymorphism at amino acid 72 is not informative for 1 lOT and 202T; showed independence ofmutation for 113T, 114T, 11ST and showed that
113T and 114T are presumably not in the germ line; CA repeat within p53 showed that the mutations in 113T, 114T, lI 5T, 1 lOT and 202T are
independent and not in the germ line.p53 mutations in breast cancer in Japanese women
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analyses is a high frequency of heterozygous rather than
hemizygous mutations in this cohort (Table I). Seven of 16
mutations were heterozygous, i.e. had equal representation of
wild-type and mutant sequence on genomic analysis. This
high frequency of heterozygosity was statistically significant
(P<0.05) when compared with all non-Japanese populations
analysed by us (Saitoh et al., 1994; Blaszyk et al., 1994;
Hartmann et al., 1995a). This observation raises the
possibility that Japanese women have greater genomic
stability, at least with respect to allelic deletion of the p53
gene, than various Western populations.
Clustering ofp53 mutations
In the present sample, independent recurrent mutations were
found at two sites (Table III). Three independent missense
mutations occurred at amino acid 273 (G:C-.A:T). This is a
known mutational hotspot occurring at a CpG site coding
for an amino acid that is conserved in all known p53
sequences (Soussi et al., 1990). This degree of conservation
extends over 1.6 billion years of evolutionary divergence. In
a database of 1965 p53 mutations (De Vries et al., 1996),
this mutation occurs 112 times (7.3%). Among 186 breast
cancer mutations, there are seven mutations at codon 273
(3.8%). There are several tumour types in which this
G:C-+A:T mutation occurs very frequently, comprising
50% of all mutations in thyroid cancers, 22.7% in
pancreatic cancer and 15.9% in brain tumours. In contrast
to this mutational hotspot, mutations at codon 183 are
extremely rare. Only one other nonsense mutation in a
bladder cancer has been reported at this location (Sidransky
et al., 1991). This 'clustering' of mutations, rather than the
mutational pattern observed could point to a common
mutagenic effect within this Japanese cohort.
Pattern ofp53 mutation
Differences in patterns of p53 gene mutations in several types
of cancer appear to reflect the effects of specific mutagens.
Examples are the relationships among G:C-+T:A transver-
sions, mutagens in cigarette smoke and lung cancer (Caron de
Fromentel and Soussi, 1992; Chiba et al., 1990); G:C-.T:A
transversions in codon 249 of the p53 gene, aflatoxin Bi
exposure and hepatocellular carcinomas (Bressac et al., 1991;
Hsu et al., 1991); and C:G-+T:A transitions and
CC:GG-TT:AA tandem dipyrimidine transitions and multi-
ple mutations, UV-B radiation and squamous and basal cell
carcinomas of the sun-exposed skin (Brash et al., 1991; Moles
et al., 1993).
In these cancers, analysis of mutations in the p53 gene
confirms associations previously recognised by classical
epidemiological studies. Identification of causative mutagens
in these tumours may have succeeded because one mutagen
predominates in each instance. In breast cancer, the risk of
disease varies at least 4-fold among different populations.
Some low-risk populations such as the Japanese have a
marked increase in risk of breast cancer when they immigrate
to a high-risk area such as the US (Stemmermann, 1991).
Classical epidemiological studies have not yet identified
unequivocally a mutagen associated with a high risk of
breast cancer in any population, perhaps because different
mutagens predominate in different populations. If so,
different high-risk populations might have different patterns
of p53 mutations since the patterns that mutagens produce
are highly variable. Several populations at high risk of breast
cancer have been shown to have different patterns of p53
gene mutation. The pattern of mutation in Midwest
Caucasian women differs significantly from that in Scottish,
Austrian and African-American females. The main differ-
ences between the populations are an abundance of
microdeletions in the US Caucasian group (Sommer et al.,
1992; Saitoh et al., 1994), a high frequency of G:C--T:A
transversions in the Scottish group (Coles et al., 1992), a high
frequency of A:T-+G:C transitions in African-Americans
(Blaszyk et al., 1994), and an abundance of A:T-+T:A
transversions in patients from Graz, Austria (Hartmann et
al., 1995a).
The Hirosaki population described in this report has a
pattern of mutation that does not have a predominant type
of mutation compared with several high-risk groups. The
pattern seen could reflect mutagenic exposure similar to other
groups as modified by genetic factors affecting processes such
as DNA repair and/or adduct formation. Alternatively, the
pattern in Hirosaki patients could reflect the baseline
(endogenous) pattern unmodified by exogenous mutagens.
In high-risk populations, a dominant mutagen or mutagens
may skew the endogenous pattern in ways that the resulting
patterns among high-risk groups differ more from each other
than from the endogenous pattern in low-risk (non-mutagen
exposed) groups. It will be difficult but important to
distinguish among these alternatives. Analysis of the pattern
of p53 mutations in breast cancers in other low-risk
populations is needed to determine if a single pattern is
characteristic of these groups. We are studying Japanese
breast cancer patients who are migrants to the US to
investigate the influence of a different lifestyle on the pattern
of p53 mutation.
Immunohistochemistry
There are numerous reports of correlations between
immunohistochemically detectable p53 expression in the
nucleus of malignant cells and the presence of a missense
mutation in the p53 gene and between absence of p53
expression and absence of p53 mutation or presence of a null
mutation (nonsense, frameshift and splice site mutation;
reviewed in Harris and Hollstein, 1993). Our previous studies
of US Caucasian (Saitoh et al., 1994), US African-American
(Blaszyk et al., 1994) and Austrian (Hartmann et al., 1995a)
cohorts of breast cancers showed a significant relationship
between nuclear expression of the p53 antigen and the
presence of a 'missense-type' mutation (missense and inframe
microdeletion/insertion). In the Hirosaki patients, although
six of eight tumours with missense mutations reacted with
PAb 1801, an anti-p53 antibody that consistently stains cells
with missense p53 mutations (JM Cunningham, personal
communication), three tumours with the same missense
change at codon 273 had different staining patterns. One
stained only with PAb 1801, one with both PAb 1801 and
PAb 240 and one did not stain, supporting the clustering of
three identical mutations at this particular codon, which is
unlikely to be due to technical artefact. As we have found in
studies of p53 mutations in other populations, the antibody
PAb240 frequently reacts with cells hemizygous or hetero-
zygous for p53 gene null mutations (JM Cunningham,
personal communication). None of the 11 tumours in which
we did not detect a p53 gene mutation stained with PAbl801
or PAb421, but two stained with PAb240. The basis of these
aberrant findings remains unclear, but they raise the
possibility of a biological difference among tumours in this
population that modifies p53 expression compared with other
cohorts previously studied by us with identical methodology.
Abbreviations
ddF, dideoxy fingerprinting; AR, androgen receptor gene; DM,
myotonic dystrophy gene; aa, amino acid.
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